SBIR/STTR Research Award

SBIR Phase II: Enabling Technologies for Noninvasive Oxygen Imaging in Regenerative Medicine

Award identifier 7d56008e631f0da83f7cb2798bcf8a5540bcc850b4b287f35a85c3a583674212Awarding agency National Science Foundation

Award amount

$1,187,210

Program and phase

SBIR · Phase II

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
O2M TECHNOLOGIES LLC
Proposal award date
2021-02-01
Contract end date
2023-01-31
UEI
RLM1GHQF3MM6
Solicitation number
Not reported
Topic code
BM

Research abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will address a major hindrance in developing efficient artificial tissues and organs designed to solve multiple health issues. Currently, poor oxygen and nutrient delivery at the core of the artificial tissues is one of the major causes of graft implantation failure. The public health benefit of replacing damaged tissues and organs is at par with curing cancer. Almost every part of the human body has been considered a candidate for tissue engineering that strives to solve many medical problems such as arthritis, Type I diabetes, stroke, vascular diseases, liver and kidney damages, etc. The technologies developed in this project will assist in the quality control of artificial tissues. This project will serve the preclinical imaging market with a dedicated oxygen imaging instrument. This Small Business Innovation Research (SBIR) Phase II project will develop technologies to address a significant shortcoming in developing artificial tissue grafts and organs. Tissue engineering regenerative medicine (TERM) is the fastest growing branch of medicine. TERM aims at the replacement or regeneration of damaged cells, tissues, or organs with artificial cell replacement devices, tissue grafts or organs, to restore normal biological function. However, the dream of artificial tissue has not been realized because of the lack of technologies that can provide maps of physiological parameters such as oxygen. The project will develop new enabling technologies for oxygen imaging in biomaterials, multi-well plate, and macro-encapsulation devices. The project will also manufacture the oxygen sensitive spin probe. It is expected that three-dimensional noninvasive oxygen imaging of tissue grafts and cell encapsulation devices will pave the way for off-the-shelf artificial tissue grafts and organs and make tissue manufacturing a reality. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

8 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $6,390,619. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.